Therapeutic potential of inhibitory VEGF splice variants.
Antiangiogenesis by inhibition of vascular endothelial growth factor (VEGF) has recently been demonstrated to be an effective therapeutic mode in human cancer alongside surgery, radiotherapy and chemotherapy. The authors have recently discovered a family of inhibitory VEGF splice variants, which has led to the possibility of using these isoforms as antiangiogenic agents. The discovery, mechanism of action, preclinical evaluation, and the potential uses of these isoforms in future cancer therapy will be discussed herein.
University of Bristol, Microvascular Research Laboratories, Department of Physiology, Preclinical Veterinary School, Southwell Street, Bristol, BS2 8EJ, UK. dave.bates@bris.ac.uk
David O
DO
Bates
Steven J
SJ
Harper
D017398:Alternative Splicing; D000595:Amino Acid Sequence; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D020033:Protein Isoforms / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D020033:Protein Isoforms; D042461:Vascular Endothelial Growth Factor A